GlassScriptPhysician profile
Adam David Scher
NPI 1255538948
$10,234.10
in general payments reported to CMS, 2019-2025
50 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,065 · 2020: $857 · 2021: $1,444 · 2022: $1,268 · 2023: $1,567 · 2024: $1,565 · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,600.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,426.26 | 2020-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $1,364.53 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Astrazeneca Pharmaceuticals LP | $818.86 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $766.33 | 2019-2025 | |
| Amgen INC. | $712.46 | 2019-2025 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $658.14 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $498.98 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $476.39 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $313.52 | 2019-2023 | Trintellix |
| Amarin Pharma, INC. | $282.69 | 2019-2022 | |
| Dexcom, INC. | $253.41 | 2020-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $242.83 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $212.38 | 2019-2025 | |
| Axsome Therapeutics, INC. | $188.46 | 2023-2025 | Auvelity |
| Exact Sciences Corporation | $172.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Scher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.